Evidence map›Paper›PMID 40206379›Full record

ArticleIranian journal of parasitology

Mohsen Arbabi, Atefeh Haddad, Seyed Mostafa Hosseipour Mashkani, Hossein Hooshyar

Abstract read
In one paragraph

Article in Iranian journal of parasitology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Assessment of oxidative stress biomarkers in liver flukeVeterinary research forum : an international quarterly journal · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohsen ArbabiDepartment of Medical Parasitology and Mycology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Atefeh HaddadDepartment of Medical Parasitology and Mycology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Seyed Mostafa Hosseipour MashkaniInstitute for Biomedical Materials and Devices, School of Mathematical and Physical Sciences, Faculty of Science, University of Technology Sydney, NSW 2007, Australia.
Hossein HooshyarDepartment of Medical Parasitology and Mycology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dicrocoeliasis is an important helminthic zoonosis reported from many parts of the world. Due to low-performance medications, drug delivery is a great challenge in improving the treatment of this liver fluke infection. We aimed to determine the anthelmintic properties of Nanosilver oxide (AgO) against Methods: The impacts of various concentrations of AgO nanoparticles (50-200 μg/ml) for 12-24 hours were compared with closantel, a chemical drug. The anthelmintic efficacy was evaluated using the scanning electron microscopy (SEM) technique. The synthesized nanoparticles were analyzed for structural assessment using XRD, UV-VIS spectroscopy, and SEM. The XRD pattern shows the formation of AgO nanoparticles. Results: The UV-VIS spectra showed the broad peak, corresponding to Ag nanoparticles. SEM images of treated parasites by AgO (200 μg/ml) showed severe damage, which includes complete loss of sensory papillae and destruction of prominent network structures and tegument vesicles. The mortality rate increases with the increase in the concentration and exposure time of the parasite to nanoparticles. Besides the MTT assay, the toxicity of AgO, at concentrations of 800 μg/ml was 8.7%. Conclusion: AgO NPs have potent anthelmintic effects on liver fluke

Indexed as

AgO nanoparticleClosantelDicrocoelium dendriticumScanning electron microscopy

Identifiers

PMID40206379
PMCPMC11978202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.